Postoperative Outcomes After Staged Versus Coordinated Breast Surgery and Bilateral Salpingo-Oophorectomy

Overview

Journal Ann Surg Oncol

Publisher Springer

Specialty Oncology

Date 2023 Jun 19

PMID 37336806

Authors

Sudheer R Vemuru

Michael Bronsert

Kristen Vossler

Victoria D Huynh

Laurel Beaty

Gretchen Ahrendt

Jaime Arruda

Christodoulos Kaoutzanis

Kristin E Rojas

Laura Bozzuto

Simon Kim

Sarah E Tevis

Affiliations

Soon will be listed here.

Abstract

Background: The objective of this study was to compare postoperative complication rates and healthcare charges between patients who underwent coordinated versus staged breast surgery and bilateral salpingo-oophorectomy (BSO).

Patients And Methods: The MarketScan administrative database was used to identify adult female patients with invasive breast cancer or BRCA1/BRCA2 mutations who underwent BSO and breast surgery (lumpectomy or mastectomy with or without reconstruction) between 2010 and 2015. Patients were assigned to the coordinated group if a breast operation and BSO were performed simultaneously or assigned to the staged group if BSO was performed separately. Primary outcomes were (1) incidence of 90-day postoperative complications and (2) 2-year aggregate perioperative healthcare charges. Fisher's exact tests, Wilcoxon rank-sum tests, and multivariable regression analyses were performed.

Results: Of the 4228 patients who underwent breast surgery and BSO, 412 (9.7%) were in the coordinated group and 3816 (90.3%) were in the staged group. The coordinated group had a higher incidence of postoperative complications (24.0% vs. 17.7%, p < 0.01), higher risk-adjusted odds of postoperative complications [odds ratio (OR) 1.37, 95% confidence interval (CI) 1.06-1.76, p = 0.02], and similar aggregate healthcare charges before (median charges: $106,500 vs. $101,555, p = 0.96) and after risk-adjustment [incidence rate ratio (IRR) 1.00, 95% CI 0.93-1.07; p = 0.95]. In a subgroup analysis, incidence of postoperative complications (12.9% for coordinated operations vs. 11.7% for staged operation, p = 0.73) was similar in patients whose breast operation was a lumpectomy.

Conclusions: While costs were similar, coordinating breast surgery with BSO was associated with more complications in patients who underwent mastectomy, but not in patients who underwent lumpectomy. These data should inform shared decision-making in high-risk patients.

Citing Articles

ASO Author Reflections: In Which Patients Should We Coordinate Breast Surgery and Bilateral Salpingo-oophorectomy?.

Vemuru S, Tevis S Ann Surg Oncol. 2023; 30(9):5681-5682.

PMID: 37210449 DOI: 10.1245/s10434-023-13673-3.

References

Bayraktar S, Arun B . BRCA mutation genetic testing implications in the United States. Breast. 2016; 31:224-232. DOI: 10.1016/j.breast.2016.11.021. View

Verheijen R, Hermsen B . The clinical implications of genetics. BRCA1- and BRCA2-positive: how do I proceed? Implications for ovarian cancer prevention. Ann Oncol. 2008; 19 Suppl 5:v84-6. DOI: 10.1093/annonc/mdn317. View

Agnantis N, Paraskevaidis E, Roukos D . Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol. 2004; 11(12):1030-4. DOI: 10.1245/ASO.2004.09.910. View

Chapman J, Roddy E, Panighetti A, Hwang S, Crawford B, Powell B . Comparing Coordinated Versus Sequential Salpingo-Oophorectomy for BRCA1 and BRCA2 Mutation Carriers With Breast Cancer. Clin Breast Cancer. 2016; 16(6):494-499. DOI: 10.1016/j.clbc.2016.06.016. View

Sroka C, Nagaraja H . Odds ratios from logistic, geometric, Poisson, and negative binomial regression models. BMC Med Res Methodol. 2018; 18(1):112. PMC: 6195979. DOI: 10.1186/s12874-018-0568-9. View

Batista L, Lu K, Beahm E, Arun B, Bodurka D, Meric-Bernstam F . Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome. BMC Cancer. 2008; 8:101. PMC: 2362122. DOI: 10.1186/1471-2407-8-101. View

Schrag D, Kuntz K, Garber J, Weeks J . Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA. 2000; 283(5):617-24. DOI: 10.1001/jama.283.5.617. View

Daly M, Pal T, Berry M, Buys S, Dickson P, Domchek S . Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021; 19(1):77-102. DOI: 10.6004/jnccn.2021.0001. View

Ma I, Gray R, Wasif N, Butler K, Cornella J, Magrina J . Outcomes of Concurrent Breast and Gynecologic Risk Reduction Surgery. Ann Surg Oncol. 2016; 24(1):77-83. DOI: 10.1245/s10434-016-5479-6. View

10.

Jayaraman A, Boyd T, Hampton S, Haddock N, Teotia S . The Impact of Combined Risk-Reducing Gynecological Surgeries on Outcomes in DIEP Flap and Tissue-Expander Breast Reconstruction. Plast Surg (Oakv). 2020; 28(2):112-116. PMC: 7298572. DOI: 10.1177/2292550320925905. View

11.

Tevis S, Steiman J, Neuman H, Greenberg C, Wilke L . Postoperative complications in combined gynecologic, plastic, and breast surgery: An analysis from National Surgical Quality Improvement Program. Breast J. 2019; 25(6):1111-1116. PMC: 7192577. DOI: 10.1111/tbj.13429. View

12.

Valachis A, Nearchou A, Lind P . Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2014; 144(3):443-55. DOI: 10.1007/s10549-014-2890-1. View

13.

Lawson E, Hall B, Louie R, Ettner S, Zingmond D, Han L . Association between occurrence of a postoperative complication and readmission: implications for quality improvement and cost savings. Ann Surg. 2013; 258(1):10-8. DOI: 10.1097/SLA.0b013e31828e3ac3. View

14.

Kauff N, Domchek S, Friebel T, Robson M, Lee J, Garber J . Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008; 26(8):1331-7. PMC: 3306809. DOI: 10.1200/JCO.2007.13.9626. View

15.

Del Corral G, Wes A, Fischer J, Serletti J, Wu L . Outcomes and Cost Analysis in High-Risk Patients Undergoing Simultaneous Free Flap Breast Reconstruction and Gynecologic Procedures. Ann Plast Surg. 2014; 75(5):534-8. DOI: 10.1097/SAP.0000000000000156. View

16.

Ludwig K, Neuner J, Butler A, Geurts J, Kong A . Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. Am J Surg. 2016; 212(4):660-669. DOI: 10.1016/j.amjsurg.2016.06.010. View

17.

Holzmer S, Davila A, Martin M . Cost Utility Analysis of Staged Versus Single-Stage Cleft Lip and Palate Repair. Ann Plast Surg. 2020; 84(5S Suppl 4):S300-S306. DOI: 10.1097/SAP.0000000000002255. View

18.

Domchek S, Friebel T, Singer C, Evans D, Lynch H, Isaacs C . Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010; 304(9):967-75. PMC: 2948529. DOI: 10.1001/jama.2010.1237. View

19.

Pierce L, Levin A, Rebbeck T, Ben-David M, Friedman E, Solin L . Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol. 2006; 24(16):2437-43. DOI: 10.1200/JCO.2005.02.7888. View

20.

AlHilli M, Al-Hilli Z . Perioperative Management of Women Undergoing Risk-reducing Surgery for Hereditary Breast and Ovarian Cancer. J Minim Invasive Gynecol. 2018; 26(2):253-265. DOI: 10.1016/j.jmig.2018.09.767. View